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ABSTRACT

Introduction The Zambian Ministry of Health (MoH)
issued COVID-19 mitigation guidance for HIV care
immediately after the first COVID-19 case was confirmed
in Zambia on 18 March 2020. The Centre for Infectious
Disease Research in Zambia implemented MoH guidance
by: 1) extending antiretroviral therapy (ART) refill duration
to 6 multi-month dispensation (6MMD) and 2) task-shifting
communication and mobilisation of those in HIV care to
Handling editor Seye Abimbola collect their next ART refill early. We assessed the impact
of COVID-19 mitigation guidance on HIV care 3 months
► Additional supplemental
material is published online only. before and after guidance implementation.
Methods We reviewed all ART pharmacy visit data in the
To view, please visit the journal
online (http://dx.d oi.org/10.
national HIV medical record for PLHIV in care having ≥1
1136/bmjgh-2021-0 07312).
visit between 1 January—30 June 2020 at 59 HIV care
facilities in Lusaka Province, Zambia. We undertook a
before–after evaluation using mixed-effects Poisson
JMP and KS contributed equally.
regression to examine predictors and marginal probability
of early clinic return (pharmacy visit >7 days before next
Received 1 September 2021
appointment), proportion of late visit (>7 days late for next
Accepted 4 January 2022
appointment) and probability of receiving a 6MMD ART
refill.
Results A total of 101 371 individuals (64% female,
median age 39) with 130 486 pharmacy visits were
included in the analysis. We observed a significant increase
in the adjusted prevalence ratio (4.63; 95% CI 4.45 to
4.82) of early return before compared with after guidance
implementation. Receipt of 6MMD increased from a weekly
mean of 47.9% (95% CI 46.6% to 49.2%) before to 73.4%
(95% CI 72.0% to 74.9%) after guidance implementation.
The proportion of late visits (8–89 days late) was
© Author(s) (or their
significantly higher before (18.8%, 95% CI17.2%to20.2%)
employer(s)) 2022. Re-use
permitted under CC BY-NC. No
compared with after (15.1%, 95% CI13.8%to16.4%)
commercial re-use. See rights
guidance implementation .
and permissions. Published by
Conclusions Timely issuance and implementation of
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COVID-19 mitigation guidance involving task-shifted
For numbered affiliations see
patient communication and mobilisation alongside 6MMD
end of article.
significantly increased early return to ART clinic, potentially
reducing interruptions in HIV care during a global public
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Dr Jake M Pry;
health emergency.
jmpry@ucdavis.e du

Key questions
What is already known?
► Limited published reports have described the im-

pact of implementing COVID-19 mitigation efforts for
people living with HIV (PLHIV), such as multimonth
dispensation (MMD) of antiretroviral therapy (ART),
on HIV care during the pandemic in sub-Saharan
Africa. Increased frequency of missed visits have
been observed in South Africa associated with
COVID-
19 lockdowns and restrictions. In well-
resourced settings, COVID-19 has been associated
with unique financial and health stressors, especially
among those in HIV care.

What are the new findings?
► We present here the impact of implementing na-

tional COVID-19 mitigation guidance using 6-month
MMD and task-shifting mobilisation of PLHIV receiving ART in Lusaka, Zambia. We observed that
individuals in care returned to ART clinic early, effectively reducing clinic patient volumes and ensuring
ART possession in preparation for initial waves of
COVID-19 in Zambia. Proactive patient communication and 6-month ART scripting resulted in increased
early return to ART clinic and potential reduction of
interruptions in HIV care during a global public health
emergency.

What do the new findings imply?
► Quickly responding and implementing COVID-
19

mitigation guidance for PLHIV using a combination
of MMD and community mobilisation can attenuate
the negative effects of external public health shocks,
such as the COVID-19 pandemic.

INTRODUCTION
The global COVID-
19 pandemic has redirected public health funding to fight SARS-
CoV-2, running the risk of undermining hard
won gains made towards ending the HIV
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epidemic in sub-Saharan Africa (SSA).1 The COVID-19
pandemic has further stressed already strained health
systems and generated widespread concerns that service
disruptions will compromise critical health functions
addressing tuberculosis (TB), HIV and malaria, among
other priority conditions, especially in resource-limited
settings.2 3 Health systems have been required to rapidly
implement modified supply chain systems and health
worker deployments, observing new public health protocols for mitigating the deleterious effects of COVID-
19. On 24 March 2020, 6 days after the first confirmed
COVID-
19 case in Zambia, the national Ministry of
Health (MoH) issued COVID-19 mitigation guidance to
HIV care facilities to prevent treatment interruption for
people living with HIV (PLHIV).2–4 This context provides
an opportunity to assess the flexibility, nimbleness and
resilience of health systems to sustain HIV treatment
services in the context of external disruptions from the
COVID-19 pandemic.
To date, relatively little data have emerged from high-
burden HIV settings, including those in SSA, to demonstrate the effects of the COVID-
19 pandemic on the
functioning of HIV treatment programmes. In South
Africa, it has been observed that 19.6% of those in HIV
care missed an HIV care appointment during the national
lockdown beginning 24 March 2020.5 There is also
evidence that PLHIV are at increased risk of COVID-19
related morbidity and mortality, highlighting the critical importance of minimising COVID-19 exposure in
this population.6 Though there has been much modelling to predict how the pandemic will impact PLHIV,
there has been commensurately little empirical data to
show how HIV treatment programmes have responded
to COVID-
19 in SSA.7–9 In programmatic settings
throughout the region, including in the southern African
country of Zambia, changes to HIV care were implemented, including introduction, adaptation and scale up
of differentiated service delivery (DSD) models, with the
intent to decongest health facilities and minimise disruptions to HIV treatment and care for PLHIV.3 10
In Zambia, access to one DSD model, multimonth
dispensing (MMD) of antiretroviral therapy (ART), has
increased since 2016. Refill intervals for ART in Zambia
have been increasing over time as ART supply chains have
become more stable and retention advantages of longer
ART refill intervals have been demonstrated.11 First, the
refill interval was extended from a standard of 1–3 months,
and prior to COVID-19, the Zambian MoH had issued
national recommendations for providing 6-month refills
for stable patients (ie, PLHIV in care ≥6 months, virally
suppressed and with minimal missed appointments).
However, scale-up of this 6MMD model had been sluggish due to limited ART stocks, differing definitions of
MMD eligibility, and other operational challenges.12 With
the emergence of COVID-19, MoH mitigation guidance
included recommendations for strengthening 6MMD
implementation, potentially increasing the probability
that an individual would receive a 6-month ART refill.
2

Given the high prevalence of HIV in Zambia, estimated
to be 11.5% of the adult (15–49 years old) population,
there is an urgent need to understand how COVID-19
mitigation guidance, including strengthened 6MMD,
impacted HIV care and treatment nationally.13 14
In this pre–post quasiexperimental analysis, we leveraged Zambia’s national HIV electronic medical record
(EMR) to evaluate the effect of the new COVID-19 mitigation recommendations on HIV care visits at public
health facilities supported by the President’s Emergency
Plan for AIDS Relief (PEPFAR), which provides approximately 97% of the HIV care funding in Zambia.15 Here,
we report changes in HIV care visits, including incidence
of early patient return, late visits and incidence of 6MMD
ART refill to estimate effects of mitigation guidance on
HIV treatment interruption during the early COVID-19
pandemic in Zambia.
METHODS
Design and patient population
We conducted a before–after cohort study involving
routine data from PLHIV in care, defined as having ≥1
documented pharmacy visit(s) between 1 January 2019
and 31 December 2019 and at ≥1 visit between 1 January
2020 and 30 June 2020 at MoH HIV care facilities in
Lusaka Province, Zambia. All pharmacy visit records were
extracted from SmartCare, which is the national HIV
EMR owned by MoH and developed and supported by
CDC/PEPFAR and its implementing partners. SmartCare serves as a comprehensive repository of all HIV-
related clinical, laboratory and pharmacy data, including
visit information, for the study population.
Setting
We included 59 MoH HIV care-
providing facilities in
Lusaka Province supported by PEPFAR/CDC. Lusaka
Province is Zambia’s most densely populated province
and includes the capital city of Lusaka. Lusaka Province
has an estimated total adult (ages 15–49 years) PLHIV
population of 202 823, with an estimated adult HIV prevalence of 11.5% in 2019.13 14
COVID-19 mitigation guidance
Zambian COVID-19 mitigation guidance functioned as
an emergent intervention to provide MMD of ART to all
PLHIV.4 16 ART provided via MMD was for a supply of 3–6
months. To implement this guidance at health facility
level, CIDRZ implementers used a phone-based community outreach strategy to proactively call back patients
with an upcoming pharmacy appointment and ask them
to present to the facility for an immediate pharmacy refill.
CIDRZ-supported lay treatment providers and community liaison officers based at the health facilities used
line-lists extracted from the SmartCare EMR, including
telephone contact information from a routine patient
locator form, to request that a patient return to the clinic
earlier than their scheduled appointment to receive ART
MMD. Community sensitisation for early clinic return for
Pry JM, et al. BMJ Global Health 2022;7:e007312. doi:10.1136/bmjgh-2021-007312
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Table 1 Characteristics of those with HIV pharmacy visits before (1 January 2020–23 March 2020 and after (24 March 2020–
30 June 2020) implementation of COVID-19 mitigation guidance
Before guidance
Factor
N
Sex
Age category (years)

1 January 2020–23 March 2020

24 March 2020–30 June 2020

Level

n (%)

n (%)

Female

64 411 (49.4)
42 048 (65.3)

66 075 (50.6)
42 393 (64.2)

Male

22 363 (34.7)

23 682 (35.8)

16–24

5457 (8.5)

4991 (7.6)

25–29

7882 (12.2)

7621 (11.5)

30–34

11 267 (17.5)

11 125 (16.8)

35–39

12 757 (19.8)

13 065 (19.8)

40–44

11 416 (17.7)

11 830 (17.9)

45–49

7684 (11.9)

8453 (12.8)

50–54

3976 (6.2)

4552 (6.9)

55–59

2210 (3.4)

2425 (3.7)

60–64

1114 (1.7)

1199 (1.8)

648 (1.0)

814 (1.2)

6871 (10.7)

6574 (9.9)

65+
Marital status

Single
Married
Divorced/widowed

Refill category (months)

35 247 (54.7)

36 486 (55.2)

7178 (11.1)

7197 (10.9)

15 115 (23.5)

15 818 (23.9)

<1

4090 (6.4)

1862 (2.8)

1–2

9788 (15.3)

9714 (14.8)

Unknown
Time in HIV care (years)

After guidance

3–4

22 134 (34.5)

23 271 (35.4)

5–9

20 547 (32.0)

21 936 (33.3)

10+

7624 (11.9)

9009 (13.7)

<1

5235 (8.4)

855 (1.3)

1–2

3977 (6.4)

964 (1.5)

20 453 (33.0)

9797 (15.1)

4–5

3

1799 (2.9)

8797 (13.5)

6
>6

24 334 (39.2)
6213 (10.0)

an extended MMD refill was also accomplished through
radio talks and mobile megaphones to reach those who
may not have a phone number on file in SmartCare.
Outcomes
We defined an ‘early return’ as a documented return
pharmacy visit occurring 8 or more days prior to an
appointment date scheduled for between 1 January 2020
and 30 June 2020. A visit was categorised as ‘on-time’ if it
occurred in a 15-day window around the next scheduled
appointment date, specifically less than 8 days before
or less than 8 days after the next scheduled appointment date. Late visit categories were defined on return
visit using the first pharmacy visit occurring after the
assigned appointment at intervals of: (1) 8–89 days late;
(2) 90–180 days late; and (3) >180 days late.17 18 ART refill
spacing, especially 6MMD refills, was assessed using the
Pry JM, et al. BMJ Global Health 2022;7:e007312. doi:10.1136/bmjgh-2021-007312

39 202 (60.3)
5401 (8.3)

pharmacy appointment interval (ie, next appointment
date minus the date of pharmacy visit).
Statistical analysis
We compared the prevalence of early return in the
preguidance period from 1 January 2020 to 23 March
2020 to the postguidance period from 24 March 2020
to 30 June 2020. Mixed effects Poisson regression
was used to estimate prevalence ratios of early return
before (preguidance) and after (postguidance) issuance of COVID-
19 mitigation guidance on 24 March
2020. Crude prevalence ratios resulted from univariate models allowing a random effect at the facility and
individual level. Adjusted estimates were the result of a
model including fixed effects for age, sex, marital status
and time in HIV care, which were identified a priori as
potential confounders for the outcome of early return,
3
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Table 2 Crude and adjusted prevalence ratios for early return (8 or more days from scheduled appointment)
Crude
Covariate

Level

Interval

Sex
Age category (years)

Marital status

Time in HIV care

PR

Adjusted
95% CI

PR

95% CI

Before (1 January 2020–23 March 1 (ref)
2020)
After (24 March 2020–30 June
4.53
2020)

ref

1 (ref)

ref

Female

ref

1 (ref)

4.37 to 4.71

4.63
1 (ref)

4.45 to 4.82
ref

Male

1.01

0.99 to 1.04

0.98

0.94 to 1.00

16–24

0.80

0.76 to 0.85

0.81

0.76 to 0.85

25–29

0.86

0.82 to 0.91

0.86

0.82 to 0.91

30–34

0.94

35–39

1 (ref)

40–44

1.05

1.01 to 1.09

1.04

1.00 to 1.09

45–49

1.12

1.07 to 1.17

1.10

1.05 to 1.15

50–54

1.19

1.13 to 1.25

1.15

1.09 to 1.21

55–59

1.20

1.12 to 1.28

1.17

1.09 to 1.25

60+

1.13

1.06 to 1.21

1.09

1.01 to 1.17

Single

1 (ref)

0.90 to 0.99
ref

ref

0.95
1 (ref)

1 (ref)

0.90 to 1.00
ref

ref

Married

1.07

1.03 to 1.11

0.94

0.90 to 0.98

Divorced/widowed

1.02

0.96 to 1.07

0.90

0.85 to 0.95

Unknown

1.04

<6 months

1 (ref)

0.99 to 1.08
ref

0.96
1 (ref)

0.92 to 1.01
ref

6–12 months

1.02

0.95 to 1.10

0.78

0.73 to 0.84

1–2 years

1.09

1.02 to 1.16

0.81

0.76 to 0.87

2–4 years

1.19

1.11 to 1.27

0.86

0.81 to 0.92

5–9 years
10+ years

1.21
1.30

1.13 to 1.28
1.20 to 1.39

0.83
0.84

0.78 to 0.89
0.78 to 0.91

Crude and adjusted model allow random effects at the facility and individual level; age category referent group specified as median.
Adjusted analysis include adjustment for visit interval, sex, age, marital status, and time in HIV care

and random effects at the individual and facility levels.
Descriptive counts and proportions were illustrated to
elucidate trends in the data over the study period. Additionally, we estimated predictive probabilities and associated 95% CIs of early visit receipt of a 6-month MMD
ART refill and of late visit.
Ethical statement
Participant consent was not required as all analyses were
conducted as part of routine CIDRZ programme monitoring and evaluation.
Patient and public involvement
COVID-19 mitigation guidelines were developed by the
Zambian MoH, and implementation of the guidance was
conducted as part of routine CIDRZ PEPFAR programming in partnership with the Zambian MOH, CDC/
PEPFAR, implementing partners and affected communities, including PLHIV. As we describe observational
results from this routine programme activity, patients in
the analysis population were not directly involved with
4

the design of the intervention or the analysis presented
here. Dissemination of study results is ongoing in consultation with CDC/PEPFAR and the CIDRZ Community
Advisory Board.
RESULTS
A total of 130 486 pharmacy visits among 101 371 PLHIV
were included in the analytical dataset. Of all individuals
included in the analysis, a majority were women (64.7%),
had a median age of 38 years (IQR: 30–45 years) and
reported being married (55.0%). Sex, age, marital status,
and years in HIV care did not differ meaningfully between
patients analysed before (1 January 2020–24 March 2020)
and after (24 March–30 June 2020) COVID-19 mitigation
guidance (issued on 24 March 2020) (table 1).
Early return visits following implementation of modified HIV
care recommendations
Those accessing HIV services in the period after
COVID-19 response guidance (ie, between 24 March and
Pry JM, et al. BMJ Global Health 2022;7:e007312. doi:10.1136/bmjgh-2021-007312
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Figure 1 Area graph of counts for attended visits and
appointments by date, before guidance (1 January 2020–23
March 2020) and after guidance (24 March 2020–30 June
2020). Note: dashed line indicates timing of before–after
transition (ie, 24 March 2020). Appointments associated with
early visits were censored.

Figure 3 Line graph of predicted probability of receiving
a 6-month refill by week before (1 January 2020–23 March
2020) and after (24 March 2020–30 June 2020) guidance with
95% CIs. Note: before–after transition occurred the week
of 18 March 2020 (ie, 24 March 2020); predicted probability
and 95% CI based on Poisson model adjusted for age, sex,
marital status, time in care and facility.

30 June 2020) returned to clinic early with an adjusted
prevalence ratio of 4.63 (95% CI 4.45 to 4.82) times
that of those in the preceding 3 month period (table 2).
The adjusted prevalence ratio (aPR) for early return was
lowest for those 16–24 years old (aPR: 0.81, 95% CI 0.76
to 0.85), followed by those 25–29 years old (aPR: 0.86,
95% CI 0.82 to 0.91). Those who were divorced/widowed
(aPR: 0.90, 95% CI 0.85 to 0.95) and those who were
married (aPR: 0.94, 95% CI 0.90 to 0.98) had a lower
adjusted prevalence ratio for early return compared with
those reporting being single. Those in care 6–12 months
had a significantly lower adjusted prevalence (aPR: 0.78,
95% CI 0.73 to 0.84) of early return compared with those
recently initiating HIV care (table 2). We also found

that the mean weekly proportion of early return in the
preguidance period was 6.2% (95% CI 5.8% to 6.5%),
significantly lower than the postguidance period with
a mean weekly proportion of 22.5% (95% CI 16.6% to
28.3%) (p value: <0.001) (figure 2).
We observed a surge of 25 758 more visits than scheduled appointments, despite relatively stable appointment
volumes, in the 4 weeks immediately following COVID-19
mitigation guidance implementation (figure 1 and
online supplemental table S1). It is also important to
note that in the last 6 weeks of the review timeframe
(20 May 2020–30 June 2020), scheduled appointments
outnumbered actual visits (figure 1 and online supplemental table S1).
Late visits following implementation of COVID-19 mitigation
guidance
There was a significant shift in the proportion (Mann-
Whitney p value: 0.002) of individuals returning ≥180
days after their scheduled appointment from the
preguidance (13.3%, 95% CI 12.8% to 13.8%) to the
postguidance period (17.2%, 95% CI 15.0% to 19.3%).
The weekly mean proportion for visits where individuals
were 8–89 days late (18.8%, 95% CI 17.2% to 20.5%) and
90–179 days late (17.0%, 95% CI to 16.6% to 17.4%) were
higher in the preguidance period compared with the
postguidance period where 8–89 days late accounted for
15.1% (95% CI 13.8% to 16.4%) of visits and 90–179 days
accounted for 14.4% (95% CI 13.8% to 15.0%) of visits
(figure 2).

Figure 2 Stacked bar chart of visit status/category among
all those with an attending visiting Lusaka Province art clinics
by week before (1 January 2020–23 March 2020) and after
guidance (24 March 2020–30 June 2020). Note: before–after
transition occurred the week of 18 March 2020 (ie, 24 March
2020).
Pry JM, et al. BMJ Global Health 2022;7:e007312. doi:10.1136/bmjgh-2021-007312

Likelihood of 6-month ART refill visits following
implementation of COVID-19 mitigation guidance
The mean proportion of those receiving a 6MMD ART
refill was significantly greater in the period after imple19 mitigation guidance (73.4%,
mentation of COVID-
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95% CI 72.0% to 74.9%) compared with the before
period (47.9%, 95% CI 46.6% to 49.2%), with a peak
probability of 83.4% (95% CI 82.8% to 84.0%), the week
of 1 April 2020 (figure 3).
DISCUSSION
We observed a significant increase in the incidence
of both early return for ART collection and use of
extended 6MMD after implementation of COVID-
19
mitigation guidance to prevent HIV treatment interruption in Lusaka, Zambia. Owing to stakeholder coordination and communication, implementation of the
guidance, including sensitising health workers, PEPFAR
partners, PLHIV and other affected communities, only
took 1 week. Collectively, these findings indicate that the
HIV treatment programme in Lusaka responded rapidly
and adapted effectively to the external shock posed by
COVID-19 through a response package involving 6MMD
and patient outreach done by lay health providers. Importantly, early return for ART was observed least frequently
among adolescents and young adults. This younger
demographic represents a priority population that has
been, traditionally, hard to reach with HIV services before
the COVID-19 pandemic and, based on our data, remain
challenging to engage in HIV programmatic innovations
during a public health emergency.
Though COVID-
19 mitigation guidance appears
to have resulted in early return for ART collection for
most PLHIV in care, it is unclear if this led to long-term
improvements in HIV care retention. It may be that early
return simply shifted appointments that would have
happened otherwise to an earlier time and reduced the
volume of facility visits over the ensuing months. However,
this result may be a worthwhile end, in and of itself, for
HIV programmes during a pandemic, as it decongests
health facilities, minimises risk of nosocomial COVID-19
transmission and helps health workers prioritise patients
having the most active HIV care issues, thereby offloading
an already overburdened health system in the throes of
COVID-19 response.
While we illustrated the successful surge of early clinic
return visits immediately following implementation of
COVID-19 mitigation guidance, there were distinct shifts
in the ratio of attended appointments to scheduled
appointment later in the pandemic. Immediately after
guidance implementation, there was an early surge when
significantly more patients attended visits compared
with scheduled visits, but later the ratio shifted to fewer
patients attending visits compared with those scheduled.
These observations could be due to one or more of the
following reasons: 1) patients readily responding to the
sensitisation, mitigation guidance and outreach efforts to
encourage early return, 2) patients being more affected
by COVID-19 and less likely to return for a visit, even for
a regularly scheduled visit and/or patients presenting to
care shortly after the first reports of COVID-19 motivated
by fears of possible facility closure or ART stock outs,
among others. It will be important to rigorously evaluate
6

incidence of lost to follow-up and continue efforts to
promote HIV care retention as COVID-19 continues to
impact HIV and other public health programmes.
Although not conclusive, our data support the concept
that telephonic communication can enable programmatic innovation and adaptation when used alongside
the following implementation strategies: community
outreach and mobilisation; task shifting to lay health
providers; and modifying pharmacy appointments . Past
research has leveraged phone-based contact with individuals lost to follow-up in Zambia and for improved HIV
testing in prevention of mother-
to-
child transmission
studies in Kenya and South Africa.19–21 Mobile network
coverage for Zambia was estiamted to be 99.1% in 2019,
compared with 74.3% 4 years prior.22 23 This rapid expansion in mobile network operations and increasingly
affordable mobile technology has opened the door for
improved efficiency and convenience for patient-provider
communication, even in settings with limited resources.
It has been noted previously that adolescents and young
adults exhibit different healthcare-
seeking behaviours
compared with older adults, which may have played a
role in the uptake of early return for ART collection seen
in our study.24–26 We observed age-related differences in
our outcomes of interest, with the lowest predictive probability of early return seen among patients ages 16–24
years. One key potential reason that we observed less early
return among younger people could be related to higher
phone number turnover in this more mobile and economically active population, especially in urban settings like
Lusaka.27 It is also possible that young people are at
increased risk for mental health stressors associated with
the COVID-19 pandemic, school or work schedule interruptions, and/or other psychosocial factors that might
impact their ability and/or availability to return early
for an ART refill.28 29 Other possible reasons could relate
to young people having more exposure to COVID-19
related misinformation on social media, or, in so far as
young people in our study lived in informal urban settlements with limited health education infrastructure, they
could have been harder to reach with health messaging
during our community outreach activities.30
PLHIV recently initiated on ART were significantly
more like to have an early return visit than those more
established on ART. This observation could be due to the
fact that those who initiated HIV care more recently may
be more likely to have a current and, thus active, phone
number documented in the EMR to enable contact by
telephonic outreach efforts. Additionally, it might be
possible that those with more treatment experience are
more comfortable with set appointments and, thus, less
receptive to early return visit because they are less likely
to want to change their appointments than patients
newer to HIV care.
Our study had several limitations. First, we included a
limited follow-up duration in the postguidance period.
However, we hypothesised that the effect of guidance
implementation would be immediate and that it would
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be possible to demonstrate that the guidance had its
intended effect shortly after implementation. While this
limited our ability to assess guidance effects on longer
term clinical outcomes like HIV care retention and
viral suppression, it likely mitigated against competing
secular trends due to the close temporal relationship
between guidance implementation and assessment of
the frequency of pharmacy visits. It will be important for
future evaluations during the COVID-19 pandemic to
closely monitor retention and viral suppression metrics
to ensure that PLHIV do not experience clinically significant treatment interruptions. Second, our analysis was
focused predominately on urban clinics, which may not
be generalisable to rural areas in Zambia. Third, we
captured only individuals in the EMR for which records
were complete, which may have excluded patients with
somewhat incomplete or incorrect records. Nonetheless,
the data for key variables has previously been found to
be highly complete and the quality of such records is
frequently audited by CIDRZ and the Zambia MoH to
address inaccuracies and update the data on a rolling
basis. Fourth, we assume that the primary contributor to
the large increase in early return visits and the decrease
in actual visits over time was due to implementation of
COVID-19 mitigation guidance and greater adoption of
6MMD, though it is possible that several other unknown
and/or unmeasured factors, such as fear of ART supply
shortages or facility closures or wanting COVID-
19
information or clinical evaluation may have played a
role. Finally, while our findings support the impact of
the COVID-
19 mitigation guidance and implementation strategies described, they do not prove causation,
which would require confirmation in larger, randomised
studies. That said, our pragmatic study design enabled us
to quickly estimate the effects of a multilevel intervention
using routinely available data during a rapidly evolving
public health emergency.

CONCLUSIONS
We showed that government COVID-19 mitigation guidance implemented using a multipronged, task-
shifted
outreach strategy can mitigate HIV care disruption
among PLHIV in care at the time of a disruption to the
public health system. It is important that patient telephone numbers and other contact details are routinely
updated, particularly for adolescents and young adults
living with HIV and that HIV programme investments
in community platforms, including lay health providers
and community sensitisation channels, are maintained to
enable their rapid leveraging to mitigate HIV treatment
interruptions during times of external shocks, such as
that caused by COVID-19.
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Table S1: Count of Actual Visits and Scheduled Appointments by Week
Week
Appointment Count
Visit Count
1-Jan-2020
5607
5898
8-Jan-2020
5789
6869
15-Jan-2020
5874
6585
22-Jan-2020
5230
6054
29-Jan-2020
6322
6935
5-Feb-2020
6830
7455
12-Feb-2020
6676
7208
19-Feb-2020
7084
7600
26-Feb-2020
7196
7255
4-Mar-2020
5409
5248
11-Mar-2020
4824
5074
18-Mar-2020
4815
5228
25-Mar-2020
3917
10533
1-Apr-2020
4799
16522
8-Apr-2020
4732
7435
15-Apr-2020
4675
6364
22-Apr-2020
4174
4560
29-Apr-2020
4379
3519
6-May-2020
4432
4071
13-May-2020
4907
3322
20-May-2020
4934
3022
27-May-2020
4304
2769
3-Jun-2020
4163
2835
10-Jun-2020
3968
2748
17-Jun-2020
4240
2664
24-Jun-2020
4026
1960
Note: date indicates the first day of the week
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